Advanced Filters
noise

Oak Park, Illinois Clinical Trials

A listing of Oak Park, Illinois clinical trials actively recruiting patient volunteers.

Found 998 clinical trials
P Pamela Manning

A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation

The purpose of this study is to assess the efficacy of Caption LungAI.

18 years of age All Phase N/A
M Mariamne Reyna

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of …

21 - 80 years of age Female Phase 1
A Amy Good

Use of CereGate Therapy for Freezing of Gait in PD

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

21 - 80 years of age All Phase N/A
R Rita Mehta, MD

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for …

18 years of age All Phase 2
M Michael Nishimura, PhD

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

18 - 89 years of age All Phase 1
D Dermatology CTU

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) …

6 years of age All Phase N/A
B Brittany Christensen

STAT: Standard Therapy Plus Active Therapy

The objective of the study is to assess the efficacy of STAT, an activity-based therapy protocol compared to standard therapy (ST) to improve functional outcome and reduce disability in patients recovering from burn injury. This randomized multi-center trial is designed with two parallel treatment groups: STAT and ST. Efficacy of …

18 - 65 years of age All Phase N/A
R Research Associate

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Study Aims Pilot study: Due to the large recruitment goal and length of the project, the study team/PIs will evaluate the first cohort of 6-10 participants to refine study procedures and study-related materials. If no major modifications are made to the protocol as a result of this evaluation, data from …

33 - 48 years of age All Phase N/A
A Anne DeBenedetti, BA

Medrol Dosepak for Outpatient Total Knee Arthroplasty

The purpose of this study is to evaluate the efficacy of an oral methylprednisolone taper on acute postoperative pain, function, opioid consumption, nausea, and complications following outpatient total knee arthroplasty (TKA). We hypothesize that administration of an oral methylprednisolone taper starting on postoperative day 1 (POD 1) following TKA will …

18 years of age All Phase 4
B Brian A. Van Tine, MD

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients …

18 years of age All Phase 1/2

Simplify language using AI